CA2375485A1 - Procede de multiplication de cellules souches - Google Patents
Procede de multiplication de cellules souches Download PDFInfo
- Publication number
- CA2375485A1 CA2375485A1 CA002375485A CA2375485A CA2375485A1 CA 2375485 A1 CA2375485 A1 CA 2375485A1 CA 002375485 A CA002375485 A CA 002375485A CA 2375485 A CA2375485 A CA 2375485A CA 2375485 A1 CA2375485 A1 CA 2375485A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- stem cells
- cells
- inhibitor
- culture medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 97
- 238000000034 method Methods 0.000 title claims description 57
- 239000003112 inhibitor Substances 0.000 claims abstract description 103
- 230000011712 cell development Effects 0.000 claims abstract description 52
- 241000282414 Homo sapiens Species 0.000 claims abstract description 32
- 230000032823 cell division Effects 0.000 claims abstract description 27
- 210000004027 cell Anatomy 0.000 claims description 125
- 239000001963 growth medium Substances 0.000 claims description 38
- 102000004127 Cytokines Human genes 0.000 claims description 21
- 108090000695 Cytokines Proteins 0.000 claims description 21
- 230000004663 cell proliferation Effects 0.000 claims description 20
- 210000001988 somatic stem cell Anatomy 0.000 claims description 18
- 230000003394 haemopoietic effect Effects 0.000 claims description 15
- 230000001413 cellular effect Effects 0.000 claims description 14
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 13
- 230000000392 somatic effect Effects 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 238000011161 development Methods 0.000 claims description 11
- 230000018109 developmental process Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 230000004069 differentiation Effects 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 230000000284 resting effect Effects 0.000 claims description 9
- 230000024245 cell differentiation Effects 0.000 claims description 8
- 230000032683 aging Effects 0.000 claims description 7
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 230000006907 apoptotic process Effects 0.000 claims description 6
- 238000006386 neutralization reaction Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 229940047124 interferons Drugs 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 4
- 108010063738 Interleukins Proteins 0.000 claims description 4
- 230000003321 amplification Effects 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 210000002216 heart Anatomy 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 229940047122 interleukins Drugs 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 4
- 210000000056 organ Anatomy 0.000 claims description 4
- 210000000496 pancreas Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 108050006400 Cyclin Proteins 0.000 claims description 3
- 102000016736 Cyclin Human genes 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 108091000080 Phosphotransferase Proteins 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 102000020233 phosphotransferase Human genes 0.000 claims description 2
- 210000001082 somatic cell Anatomy 0.000 claims description 2
- 230000024642 stem cell division Effects 0.000 claims description 2
- 108091007914 CDKs Proteins 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 19
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 19
- 230000000903 blocking effect Effects 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 102000015215 Stem Cell Factor Human genes 0.000 description 4
- 108010039445 Stem Cell Factor Proteins 0.000 description 4
- 102000036693 Thrombopoietin Human genes 0.000 description 4
- 108010041111 Thrombopoietin Proteins 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 108700014844 flt3 ligand Proteins 0.000 description 3
- SXXHYAMKYMNIHI-UHFFFAOYSA-N fluoroimino(sulfanylidene)methane Chemical compound FN=C=S SXXHYAMKYMNIHI-UHFFFAOYSA-N 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 102000018728 Inhibitor of Differentiation Proteins Human genes 0.000 description 2
- 108010052370 Inhibitor of Differentiation Proteins Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 108700025701 Retinoblastoma Genes Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 108700029231 Developmental Genes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003443 anti-oncogenic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- -1 bar Proteins 0.000 description 1
- 108700041737 bcl-2 Genes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000011773 genetically engineered mouse model Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR99/07011 | 1999-06-03 | ||
| FR9907011A FR2794473B1 (fr) | 1999-06-03 | 1999-06-03 | Procede de multiplication de cellules souches |
| PCT/FR2000/001486 WO2000075290A1 (fr) | 1999-06-03 | 2000-05-30 | Procede de multiplication de cellules souches |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2375485A1 true CA2375485A1 (fr) | 2000-12-14 |
Family
ID=9546326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002375485A Abandoned CA2375485A1 (fr) | 1999-06-03 | 2000-05-30 | Procede de multiplication de cellules souches |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7601534B1 (https=) |
| EP (1) | EP1181354A1 (https=) |
| JP (1) | JP2003501081A (https=) |
| CA (1) | CA2375485A1 (https=) |
| FR (1) | FR2794473B1 (https=) |
| WO (1) | WO2000075290A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005077404A1 (en) | 2004-02-13 | 2005-08-25 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
| CA2582567A1 (en) * | 2004-10-07 | 2006-04-13 | Stem Cell Therapeutics Corp. | Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds |
| KR20080103108A (ko) * | 2006-03-17 | 2008-11-26 | 스템 셀 테라퓨틱스 코포레이션 | 신경 장애 치료를 위한 ｌｈ 또는 ｈｃｇ 및 ｅｐｏ의 투여방법 |
| GB201111244D0 (en) * | 2011-06-30 | 2011-08-17 | Konink Nl Akademie Van Wetenschappen Knaw | Culture media for stem cells |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| ES2579909T3 (es) | 2009-02-03 | 2016-08-17 | Koninklijke Nederlandse Akademie Van Wetenschappen | Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre |
| WO2011069091A1 (en) | 2009-12-04 | 2011-06-09 | Boston Biomedical Research Institute, Inc. | Method for cloning pluripotent stem cells |
| US9164079B2 (en) * | 2011-03-17 | 2015-10-20 | Greyledge Technologies Llc | Systems for autologous biological therapeutics |
| US9249394B2 (en) | 2011-03-25 | 2016-02-02 | Kyoto University | Method for producing epithelial stem cells |
| GB201721615D0 (en) | 2017-12-21 | 2018-02-07 | Koninklijke Nederlandse Akademie Van Wetenschappen | Immune cell organoid co-cultures |
| WO2024259127A2 (en) * | 2023-06-13 | 2024-12-19 | The Children's Medical Center Corporation | Methods for generating human amniotic membrane and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH08205860A (ja) * | 1994-01-21 | 1996-08-13 | Usa Government | 造血細胞の膨大化および移植方法 |
| DE4422667A1 (de) * | 1994-06-30 | 1996-01-04 | Boehringer Ingelheim Int | Verfahren zur Herstellung und Züchtung hämatopoetischer Vorläuferzellen |
| EP0891419A4 (en) * | 1996-03-12 | 2000-03-01 | Life Technologies Inc | NUTRIENT ADDITIVE FOR HEMATOPOETIC CELL CULTURES |
| EP0834556A1 (en) * | 1996-09-25 | 1998-04-08 | Academisch Ziekenhuis Leiden | Methods for culturing cells |
| JPH10136978A (ja) * | 1996-11-08 | 1998-05-26 | Otsuka Pharmaceut Co Ltd | 造血幹細胞の培養方法 |
| US6084060A (en) * | 1996-12-09 | 2000-07-04 | Imclone Systems Incorporated | Composition and method for preserving progenitor cells |
| JPH10295369A (ja) * | 1997-02-26 | 1998-11-10 | Japan Tobacco Inc | 造血幹細胞の製造方法 |
-
1999
- 1999-06-03 FR FR9907011A patent/FR2794473B1/fr not_active Expired - Fee Related
-
2000
- 2000-05-30 EP EP00936985A patent/EP1181354A1/fr not_active Withdrawn
- 2000-05-30 JP JP2001502556A patent/JP2003501081A/ja active Pending
- 2000-05-30 WO PCT/FR2000/001486 patent/WO2000075290A1/fr not_active Ceased
- 2000-05-30 CA CA002375485A patent/CA2375485A1/fr not_active Abandoned
- 2000-05-30 US US09/980,484 patent/US7601534B1/en not_active Expired - Fee Related
-
2009
- 2009-09-08 US US12/555,062 patent/US20090325289A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000075290A1 (fr) | 2000-12-14 |
| FR2794473B1 (fr) | 2003-09-26 |
| EP1181354A1 (fr) | 2002-02-27 |
| US7601534B1 (en) | 2009-10-13 |
| FR2794473A1 (fr) | 2000-12-08 |
| US20090325289A1 (en) | 2009-12-31 |
| JP2003501081A (ja) | 2003-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4146802B2 (ja) | 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用 | |
| JP4336821B2 (ja) | 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導 | |
| US20090325289A1 (en) | Process for the multiplication of stem cells | |
| Bagley et al. | Extended culture of multipotent hematopoietic progenitors without cytokine augmentation in a novel three-dimensional device | |
| EP0789074B1 (fr) | Equivalent de peau comprenant des cellules de Langerhans | |
| Mortera-Blanco et al. | Long-term cytokine-free expansion of cord blood mononuclear cells in three-dimensional scaffolds | |
| CA2963756C (fr) | Methode de generation de progeniteurs de cellules t | |
| FR2836924A1 (fr) | Lignees de cellules aviaires utiles pour la production de substances d'interet | |
| KR20040029311A (ko) | 다능성 줄기 세포의 동종이식편의 내성화 | |
| FR2461002A1 (fr) | Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede | |
| CN103442724A (zh) | 含有可从机体组织中分离的ssea-3阳性的多能干细胞的同种异体移植用细胞治疗用组合物 | |
| EP0800575B1 (fr) | Procede de transfert de gene dans des cellules activees a partir d'un etat de repos | |
| WO2021049617A1 (ja) | ヒト造血幹細胞を培養するために適したアルブミンフリーの無血清培地およびアルブミンフリーの培養方法 | |
| WO2003083091A1 (de) | Dedifferenzierte, programmierbare stammzellen monozytären ursprungs, sowie deren herstellung und verwendung | |
| FR3079239A1 (fr) | Nouvelle methode d’obtention de cellules t a partir de cellules souches pluripotentes, et leurs utilisations | |
| Wu et al. | Contribution of mesenchymal progenitor cells to tissue repair in rat cardiac allografts undergoing chronic rejection | |
| FR2665175A1 (fr) | Equivalent d'epiderme, son procede d'obtention et son utilisation. | |
| JP6446222B2 (ja) | 軟骨分化培養液、及び軟骨組織の製造方法 | |
| US20240392248A1 (en) | Human bone marrow-derived mesenchymal stem cell sheets and methods for their production | |
| EP1960011B1 (fr) | Utilisation d' un polysaccharide excrete par l'espece vibrio diabolicus a des fins d'ingenierie des tissus conjonctifs non mineralises | |
| WO2021227573A1 (zh) | 无异源培养基及使用其扩增间充质干细胞的方法 | |
| CA3198833A1 (en) | Production of megakaryocytes and platelets in a co-culture system | |
| EP3875580A1 (en) | Methods for preparing keratinocytes | |
| FR3112558A1 (fr) | Procede d’amplification in vitro ou ex vivo de cellules souches d’adipocytes bruns ou beiges | |
| CA3125836A1 (fr) | Procede d'amplification in vitro ou ex vivo de cellules souches du tissu adipeux humain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |